Managing overactive bladder

References

• Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynaecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 2010;21:5–26
   PubMed Web of Science ®Google Scholar
• Stewart WF, Corey R, Herzog AR, et al. Prevalence of overactive bladder in women: results from the NOBLE program. Int Urogynaecol J 2001;12:S66
   Google Scholar
• Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87:760–6
   PubMed Web of Science ®Google Scholar
• Anderson KE. The overactive bladder: pharmacologic basis of drug treatment. Urology 1997;50:74–89
   PubMed Web of Science ®Google Scholar
• Hashim H, Abrams P. Is the bladder a reliable witness for predicting detrusor overactivity? J Urol 2006;175:191–5
   PubMed Web of Science ®Google Scholar
• Caulfield MP, Birdsall NJ. International union of pharmacology XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998;50:279
   PubMed Web of Science ®Google Scholar
• Braverman AS, Ruggieri MR. The M2 receptor contributes to contraction of the denervated rat urinary bladder. Am J Physiol 1998;275:1654
   Web of Science ®Google Scholar
• Cartwright R, Panayi D, Cardozo L, Khullar V. Reliability and normal ranges for the patient’s perception of intensity of urgency scale in asymptomatic women. BJU Int 2010;105:832–6
   PubMed Web of Science ®Google Scholar
• Cardozo L, Coyne KS, Versi E. Validation of the urgency perception scale. BJU Int 2005;95:591–6
   PubMed Web of Science ®Google Scholar
• Nixon A, Colman S, Sabounjian L, et al. A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J Urol 2005;174:604–7
   PubMed Web of Science ®Google Scholar
• Jenkinson C, Coulter A, Wright L. Short Form 36 (SF-36) health survey questionnaire. Normative data for adults of working age. Br Med J 1993;306:1437–40
   PubMed Web of Science ®Google Scholar
• Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 1997;104:1374–9
   PubMedGoogle Scholar
• Swithinbank L, Hashim H, Abrams P. The effect of fluid intake on urinary symptoms in women. J Urol 2005;174:187–9
   PubMed Web of Science ®Google Scholar
• Subak LL, Wing R, West DS, et al. PRIDE investigators. Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med 2009;360:481–90
   PubMed Web of Science ®Google Scholar
• Jeffcoate TNA, Francis WJA. Urgency incontinence in the female. Am J Obstet Gynecol 1966;94:604–18
   PubMed Web of Science ®Google Scholar
• Berghmans LC, Hendricks HJ, de Bie RA, et al. Conservative treatment of urge urinary incontinence in women: a systematic review of randomised clinical trials. Br J Urol Int 2000;85:254–63
   Google Scholar
• NICE Guideline 40. The Management of Urinary Incontinence in Women. Department of Health. www.nice.org.uk. 2013
   Google Scholar
• Dumoulin C, Adewuyi T, Booth J, et al. Adult conservative management. In Abrams P, Cardozo L, Wagg A, Wein A. ed. Incontinence, 6th ed. IUCD ICS; 2017: 1443–1628
   Google Scholar
• Prasad Rai B, Cody JD, Alhasso AA, Stewart L. Anticholinergic drugs versus non drug active therapies for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2012;12:CD003193
   PubMed Web of Science ®Google Scholar
• Andersson KE, Cardozo L, Cruz F, et al. Pharmacological treatment of urinary incontinence. In Abrams P, Cardozo L, Wagg A, Wein A. ed. Incontinence. 6th ed. IUCD ICS; 2017: 805–958
   Google Scholar
• Hadorn DC, Baker D, Hodges JS, Hicks N. Rating the quality of evidence for clinical practice guidelines. J Clin Epidemiol 1996;49:749–54
   PubMed Web of Science ®Google Scholar
• Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ 2001;323:334–6
   PubMed Web of Science ®Google Scholar
• Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54:543–62
   PubMed Web of Science ®Google Scholar
• Araklitis G, Thiagamoorthy G, Hunter J, et al. Anticholinergic prescription: are healthcare professionals the real burden? Int Urogynaecol J 2017;28:1249–56
   PubMed Web of Science ®Google Scholar
• Fox C, Smith T, Maidment I, et al. Effect of medications with anticholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing 2014;43:604–15
   PubMed Web of Science ®Google Scholar
• Fox C, Richardson K, Maidment ID, et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc 2011;59:1477–83
   PubMed Web of Science ®Google Scholar
• Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med 2015;175:401–7
   PubMed Web of Science ®Google Scholar
• www.ageingbraincare.org/uploads/products/ACB_Scale_-_legal_size.pdf
   Google Scholar
• Andersson KE, Arner A. Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev 2004;84:935–86
   PubMed Web of Science ®Google Scholar
• Otsuka A, Shinbo H, Matsumoto R, Kurita Y, Ozono S. Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium. Naunyn Schmiedebergs Arch Pharmacol 2008;377:473–81
   PubMed Web of Science ®Google Scholar
• Sacco E, Bientinesi R, Tienforti D, et al. Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence. Expert Opin Drug Discov 2014;9:433–48
   PubMed Web of Science ®Google Scholar
• Hicks A, McCafferty GP, Riedel E, et al. GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog. J Pharmacol Exp Ther 2007;323:202–9
   PubMed Web of Science ®Google Scholar
• Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a beta 3 adrenceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase III trial. Eur Urol 2013;63:283–95
   PubMed Web of Science ®Google Scholar
• Chapple CR, Kaplan SA, Mitcheson D, et al. Randomised double-blind, active-controlled phase III study to assess 12 month safety and efficacy of mirabegron, a beta 3 adrenoceptor agonist, in overactive bladder. Eur Urol 2013;63:296–305
   PubMed Web of Science ®Google Scholar
• Drake MJ, Chapple C, Esen AA, et al. BESIDE investigators. Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double blind multicentre phase 3B study (BESIDE). Eur Urol 2016;70:136–45
   PubMed Web of Science ®Google Scholar
• Cheng CL, Li JR, Lin CH, de Groat WC. Positive association of female overactive bladder symptoms and oestrogen deprivation: A nationwide population based cohort survey in Taiwan. Medicine (Baltimore) 2016;95:e4107
   PubMed Web of Science ®Google Scholar
• Hong SK, Yang JH, Kim TB, Kim SW, Paick JS. Effects of ovariectomy and oestrogen replacement on the function and depression of Rho-kinase in rat bladder smooth muscle. BJU Int 2006;98:1114–17
   PubMed Web of Science ®Google Scholar
• Yoshida J, Aikawa K, Yoshimura Y, et al. The effects of ovariectomy and oestrogen replacement on acetylcholine release from nerve fibres and passive stretch induced acetylcholine release in female rats. Neurourol Urodyn 2007;26:1050–5
   PubMed Web of Science ®Google Scholar
• Petkov GV. Central role of the BK channel in urinary bladder smooth muscle physiology and pathophysiology. Am J Physiol Requl Integr Comp Physiol 2014;307:R571–584
   PubMed Web of Science ®Google Scholar
• Xin W, Li N, Fernandes VS, et al. BK Channel regulation by phosphodiesterase type 1: a novel signaling pathway controlling human detrusor smooth muscle function. Am J Physiol Renal Physiol 2016;310:F994–9
   PubMed Web of Science ®Google Scholar
• Provence A, Hristov KL, Parajuli SP, Petkov GV. Regulation of guinea pig detrusor smooth muscle excitability by 17β oestradiol: the role of the large conductance voltage and Ca2+ activated K+ channels. PLoS One 2015;10:e0141950
   PubMed Web of Science ®Google Scholar
• Hristov KL, Parajuli SP, Provence A, Rovner ES, Petkov GV. Nongenomic modulation of the larger conductance voltage and Ca2+ activated K+ channels by oestrogen: a novel regulatory mechanism in human detrusor smooth muscle. Physiol Rep 2017;5:e13351
   PubMed Web of Science ®Google Scholar
• Chen HY, Chen CJ, Chen WC, Wang SJ, Chen YH. A promising protein responsible for overactive bladder in ovariectomised mice. Taiwan J Obstet Gynaecol 2017;56:196–203
   PubMed Web of Science ®Google Scholar
• Samsioe G, Jansson I, Mellstrom D, Svanberg A. Urinary incontinence in 75 year old women. Effects of oestriol. Acta Obstet Gynaecol Scand 1985;93:57
   Google Scholar
• Cardozo LD, Rekers H, Tapp A, et al. Oestriol in the treatment of postmenopausal urgency: a multicentre study. Maturitas 1993;18:47–53
   PubMed Web of Science ®Google Scholar
• Benness C, Wise BG, Cutner A, Cardozo LD. Does low dose vaginal oestradiol improve frequency and urgency in postmenopausal women. Int Urogynaecol J 1992;3:281
   Google Scholar
• Eriksen PS, Rasmussen H. Low dose 17β-oestradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo controlled study. Eur J Obstet Gynaecol Reprod Biol 1992;44:137–44
   PubMed Web of Science ®Google Scholar
• Cardozo L, Lose G, McClish D, Versi E. Estrogen treatment for symptoms of an overactive bladder, results of a meta analysis. Int J Urogynaecol 2001;12:V
   Google Scholar
• Tseng LH, Wang AC, Chang YL, et al. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome. Neurourol Urodyn 2009;28:47–51
   PubMed Web of Science ®Google Scholar
• Nelken RS, Ozel BZ, Leegant AR, Felix JC, Mishell DR. Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder. Menopause 2011;18:962–6
   PubMed Web of Science ®Google Scholar
• Jiang F, Zhu L, Xu T, et al. Efficacy and safety of solifenacin succinate tablets versus solifenacin succinate tablets with local estrogen for the treatment of overactive bladder in postmenopausal women – a multicenter, randomized, open label, controlled comparison study. Menopause 2016;23:451–7
   PubMed Web of Science ®Google Scholar
• Chughtai B, Forde JC, Buck J, et al. The concomitant use of fesoterodine and topical vaginal oestrogen in the management of overactive bladder and sexual dysfunction in post menopausal women. Post Reprod Health 2016;22:34–40
   PubMedGoogle Scholar
• Serati M, Salvatore S, Uccella S, Cardozo L, Bolis P. Is there a synergistic effect of topical oestrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity? Eur Urol 2009;55:713–19
   PubMed Web of Science ®Google Scholar
• Nitti V, Dmochowski R, Herschorn S, et al., EMBARK Study Group. Onabotulinumtoxin A for the treatment of patients with overactive bladder and urinary incontinence: results of a phase III randomised placebo controlled trial. J Urol 2013;189:2186–93
   PubMed Web of Science ®Google Scholar
• Peters KM, Macdiarmid SA, Wooldridge LS, et al. Randomised trial of percutaneous tibial nerve stimulation versus extended release tolterodine: results from the overactive bladder innovative therapy trial. J Urol 2009;182:1055–61
   PubMed Web of Science ®Google Scholar
• Burton C, Sajja A, Latthe PM. Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: a systematic review and meta-analysis. Neurourol Urodyn 2012;31:1206–16
   PubMed Web of Science ®Google Scholar
• van der Pal F, van Balken MR, Heesakkers JP, Debruyne FM, Bemelmans BL. Percutaneous tibial nerve stimulation in the treatment of refractory overactive bladder syndrome: is maintenance treatment necessary? BJU Int 2006;97:547–50
   PubMed Web of Science ®Google Scholar
• Peters KM, Carrico DJ, Macdiarmid SA, et al. Sustained therapeutic effects of percutaneous tibial nerve stimulation: 24-month results of the STEP study. Neurourol Urodyn 2013;32:24–9
   PubMed Web of Science ®Google Scholar
• Oerlemans DJ, van Kerrebroeck PE. Sacral nerve stimulation for neuromodulation of the lower urinary tract. Neurourol Urodyn 2008;27:28–33
   PubMed Web of Science ®Google Scholar
• Monga AK, Tracey MR, Subbaroyan. A systematic review of clinical studies of electrical stimulation for treatment of lower urinary tract dysfunction. Int Urogynecol J 2012;23:993–1005
   PubMed Web of Science ®Google Scholar
• Groen J, Blok BF, Bosch JL. Sacral neuromodulation as treatment for refractory idiopathic urge urinary incontinence: 5-year results of a longitudinal study in 60 women. J Urol 2011;186:954–9
   PubMed Web of Science ®Google Scholar